

Table S1. Association between IL-6 polymorphisms in allele and genotype models and clinicopathological features.

Parameter	IL-6 rs1800795										IL-6 rs1800797									
	Allelic model					Genotype model					Allelic model					Genotype model				
	C allele non carriers	C allele carriers	G allele non carriers	G allele carriers	P-value	CC	GC	GG	A allele non carriers	A allele carriers	G allele non carriers	G allele carriers	AA	GA	GG	P-value				
Age at diagnosis, years																				
<50	41	99	34	106		34	65	41		41	99	37	103		37	62	41			
≥50	24	38	15	47		15	23	24		20	42	15	47		15	27	20			
OR (95% CI)	1	1.53 (0.81-2.86)	1	0.99 (0.49-1.99)		1	0.99 (0.49-1.99)			1	1.15 (0.60-2.19)	1	0.89 (0.45-1.78)		1	0.89 (0.45-1.78)				
P-value		0.194		1.000			0.363				0.392		0.862			0.924				
Tumour size, cm																				
<2	41	89	29	101		29	60	41		38	92	32	98		32	60	38			
2-5	24	48	20	52		20	28	24		23	49	20	52		20	29	23			
OR (95% CI)	1	1.09 (0.59-2.01)	1	1.34 (0.69-2.59)		1	1.34 (0.69-2.59)			1	1.14 (0.61-2.12)	1	1.18 (0.61-2.26)		1	1.18 (0.61-2.26)				
P-value		0.887		0.393			0.554				0.750		0.619			0.745				
Lymph node status																				
Negative	39	83	29	93		29	54	39		34	88	33	89		33	55	34			
Positive	26	54	20	60		20	34	26		27	53	19	61		19	34	27			
OR (95% CI)	1	1.03 (0.56-1.87)	1	1.07 (0.56-2.06)		1	1.07 (0.56-2.06)			1	1.32 (0.72-2.43)	1	0.84 (0.44-1.61)		1	0.84 (0.44-1.61)				
P-value		1.000		0.498			0.965				0.434		0.626			0.665				
Differentiation grade																				
G1+G2	50	107	39	118		39	68	50		46	111	40	117		40	71	46			
G3	15	29	10	34		10	19	15		15	29	12	32		12	17	15			
OR (95% CI)	1	1.11 (0.55-2.25)	1	0.89 (0.40-1.97)		1	0.89 (0.40-1.97)			1	1.25 (0.61-2.54)	1	1.10 (0.52-2.33)		1	1.10 (0.52-2.33)				
P-value		0.862		0.857			0.976				0.580		0.846			0.743				
Estrogen receptor status																				
Positive	38	100	32	106		32	68	38		34	104	38	100		38	71	34			
Negative	27	37	17	47		17	20	27		27	37	27	37		27	18	27			
OR (95% CI)	1	1.92 (1.04-3.57)	1	1.19 (0.61-2.37)		1	1.19 (0.61-2.37)			1	2.23 (1.19-4.08)	1	1.09 (0.52-2.33)		1	1.09 (0.52-2.33)				
P-value		0.040 ^a		0.361			0.038 ^a				0.014 ^a		0.846			0.005 ^a				
Progesterone receptor status																				
Positive	37	84	24	97		24	60	37		32	89	25	96		25	64	32			
Negative	28	53	25	56		25	28	28		29	52	27	54		27	25	29			
OR (95% CI)	1	1.20 (0.66-2.18)	1	1.80 (0.94-3.46)		1	1.80 (0.94-3.46)			1	1.55 (0.85-2.85)	1	1.92 (1.01-3.63)		1	1.92 (1.01-3.63)				
P-value		0.654		0.092			0.071				0.161		0.050			0.007 ^a				

Table SI. Continued.

Parameter	<i>IL-6</i> rs1800795						<i>IL-6</i> rs1800797							
	Allelic model			Genotype model			Allelic model			Genotype model				
	C allele non carriers	C allele carriers	G allele non carriers	G allele carriers	CC	GC	GG	A allele non carriers	A allele carriers	G allele non carriers	G allele carriers	AA	GA	GG
Human epidermal growth factor receptor 2 status														
Negative	48	116	42	122	42	74	48	44	120	45	119	45	75	44
Positive	17	21	7	31	7	14	17	17	21	7	31	7	14	17
OR (95% CI)	1	1.96 (0.95-4.03)	1	0.66 (0.27-1.60)	1	2.21 (1.07-4.57)	1	2.21 (1.07-4.57)	0.042 ^a	1	0.59 (0.25-1.45)	1	0.59 (0.25-1.45)	0.105
P-value		0.083		0.401		0.194					0.307			

^aSignificant. OR, odds ratio.

Table SII. Association between IL-6 polymorphisms in haplotype and diplotype models and clinicopathologic features.

Parameter	Haplotype model				Diplotype model		
	GG haplotype noncarriers	GG haplotype carriers	AC haplotype non carriers	AC haplotype carriers	AC/AC	GG/AC	GG/GG
Age at diagnosis, years							
<50	38	102	42	98	34	58	43
≥50	17	45	24	38	14	22	20
OR (95% CI)	1	1.01 (0.52-1.98)	1	1.48 (0.79-2.75)			
P-value		>0.999		0.256	0.825		
Tumour size, cm							
<2	34	96	41	89	29	54	41
2-5	21	51	25	47	19	26	22
OR (95% CI)	1	1.16 (0.61-2.21)	1	1.16 (0.63-2.13)			
P-value		0.742		0.642	0.718		
Lymph node status							
negative	35	87	39	83	29	48	36
positive	20	60	27	53	19	32	27
OR (95% CI)	1	0.83 (0.44-1.57)	1	1.08 (0.59-1.98)			
P-value		0.629		0.878	0.929		
Differentiation grade							
G1+G2	43	114	51	106	38	62	48
G3	12	32	15	29	10	17	15
OR (95% CI)	1	0.99 (0.46-2.11)	1	1.08 (0.53-2.18)			
P-value		>0.999		0.857	0.926		
Estrogen receptor status							
Positive	36	102	35	102	31	62	36
Negative	19	45	27	37	17	18	27
OR (95% CI)	1	1.20 (0.62-2.31)	1	2.13 (1.14-3.98)			
P-value		0.355		0.018 ^a	0.028 ^a		
Progesterone receptor status							
Positive	28	93	37	84	23	55	35
Negative	27	54	29	52	25	25	28
OR (95% CI)	1	1.66 (0.89-3.11)	1	1.27 (0.69-2.29)			
P-value		0.146		0.448	0.052		
Human epidermal growth factor receptor 2 status							
Negative	47	117	48	114	41	68	46
Positive	8	30	18	22	7	12	17
OR (95% CI)	1	0.66 (0.28-1.55)	1	1.94 (0.94-4.44)			
P-value		0.230		0.095	0.155		

^aSignificant. OR, odds ratio.

Table SIII. Associations between *IL-1α* rs1800587 polymorphism and clinicopathological features.

Parameter	Allelic model				Genotype model		
	G allele non carriers	G allele carriers	A allele non carriers	A allele carriers	GG	GA	AA
Age at diagnosis, years							
<50	14	126	68	72	68	58	14
≥50	4	58	29	33	29	29	4
OR (95% CI)	1	0.62 (0.19-1.97)	1	0.93 (0.51-1.69)			
P-value		0.593		0.879	0.631		
Tumour size, cm							
2-5 cm	2	70	41	31	41	29	2
<2	16	114	56	74	56	58	16
OR (95% CI)	1	4.91 (1.09-22.01)	1	0.57 (0.32-1.02)			
P-value		0.022 ^a		0.077	0.032 ^a		
Lymph node status							
Negative	14	108	56	66	56	52	14
Positive	4	76	41	39	41	35	4
OR (95% CI)	1	0.41 (0.13-1.28)	1	1.24 (0.70-2.18)			
P-value		0.135		0.475	0.252		
Differentiation grade							
G1+G2	13	144	74	83	74	70	13
G3	5	39	23	21	23	16	5
OR (95% CI)	1	1.42 (0.48-4.23)	1	1.23 (0.63-2.39)			
P-value		0.553		0.610	0.579		
Estrogen receptor status							
Positive	12	126	63	75	63	63	12
Negative	6	58	34	30	34	24	6
OR (95% CI)	1	1.09 (0.39-3.04)	1	1.35 (0.75-2.45)			
P-value		>0.999		0.365	0.547		
Progesterone receptor status							
Positive	12	109	55	66	55	54	12
Negative	6	75	42	39	42	33	6
OR (95% CI)	1	0.73 (0.26-2.02)	1	1.29 (0.74-2.27)			
P-value		0.621		0.392	0.627		
Human epidermal growth factor receptor 2 status							
Negative	15	149	79	85	79	70	15
Positive	3	35	18	20	18	17	3
OR (95% CI)	1	0.85 (0.23-3.10)	1	0.97 (0.48-1.96)			
P-value		>0.999		>0.999	0.956		

^aSignificant. OR, odds ratio.

Table SIV. Association between *IL-1β* polymorphisms and clinicopathological features.

Parameter	<i>IL-1β</i> rs1143634						<i>IL-1β</i> rs16944						
	Allelic model			Genotype model			Allelic model			Genotype model			
	A allele carriers	A allele carriers	G allele non carriers	AA	GA	GG	A allele carriers	A allele carriers	G allele non carriers	AA	GA	GG	
Age at diagnosis, years													
<50	67	73	10	10	63	67	60	80	11	129	11	69	60
≥50	32	30	4	4	26	32	26	36	3	59	3	33	26
OR (95% CI)	1	1.16 (0.64-2.11)	1	0.89 (0.27-2.98)			1	0.96 (0.53-1.76)	1	0.59 (0.16-2.22)			
P-value		0.650		>0.999		0.942		>0.999		0.557			0.789
Tumour size, cm													
<2	60	70	11	11	59	60	58	72	11	119	11	61	58
2-5	39	33	3	3	30	39	28	44	3	69	3	41	28
OR (95% CI)	1	1.38 (0.77-2.46)	1	0.47 (0.13-1.74)			1	0.79 (0.44-1.42)	1	0.47 (0.13-1.74)			
P-value		0.305		0.387		0.390		0.460		0.387			0.317
Lymph node status													
Negative	56	66	8	8	58	56	50	72	8	114	8	64	50
Positive	43	37	6	6	31	43	36	44	6	74	6	38	36
OR (95% CI)	1	1.37 (0.78-2.41)	1	1.16 (0.39-3.47)			1	1.18 (0.67-2.08)	1	1.16 (0.39-3.47)			
P-value		0.315		0.785		0.462		0.663		0.785			0.808
Differentiation grade													
G1+G2	80	77	148	9	68	80	68	89	9	148	9	80	68
G3	19	25	9	5	20	19	17	27	5	39	5	22	17
OR (95% CI)	1	0.73 (0.37-1.44)	1	2.11 (0.67-6.65)			1	0.82 (0.42-1.63)	1	2.11 (0.67-6.65)			
P-value		0.397		0.857		0.327		0.609		0.194			0.396
Estrogen receptor status													
Negative	32	32	6	6	26	32	24	40	5	59	5	35	24
Positive	67	71	8	8	63	67	62	76	9	129	9	67	62
OR (95% CI)	1	0.94 (0.52-1.71)	1	0.59 (0.19-1.79)			1	1.36 (0.74-2.49)	1	0.82 (0.26-2.56)			
P-value		0.881		0.379		0.558		0.361		0.769			0.591
Progesterone receptor status													
Negative	42	39	7	7	32	42	34	47	7	71	7	40	34
Positive	57	64	7	7	57	57	52	69	7	114	7	62	52
OR (95% CI)	1	0.83 (0.47-1.45)	1	0.65 (0.22-1.93)			1	1.04 (0.59-1.84)	1	0.65 (0.22-1.93)			
P-value		0.57		0.573		0.489		>0.999		0.573			0.768

Table SIV. Continued.

Parameter	<i>IL-1β</i> rs1143634				<i>IL-1β</i> rs16944										
	Allelic model		Genotype model		Allelic model		Genotype model								
	A allele non carriers	A allele carriers	G allele non carriers	G allele carriers	AA	GA	GG	A allele non carriers	A allele carriers	G allele non carriers	G allele carriers				
Human epidermal growth factor receptor 2 status															
Negative	77	87	10	154	10	77	77	67	97	9	155	9	88	67	
Positive	22	16	4	34	4	12	22	19	19	5	33	5	14	19	
OR (95% CI)	1	1.55 (0.76-3.17)	1	1.81 (0.54-6.12)				1	1.45 (0.71-2.94)	1	2.61 (0.82-8.29)		AA	GA	GG
P-value		0.280		0.305					0.363		0.146				0.086

OR, odds ratio.

Table SV. Association between *VEGFA* rs699947 and *VEGFA* rs833061 polymorphisms and clinicopathologic features.

Parameter	VEGFA rs699947						VEGFA rs833061						
	Allelic model			Genotype model			Allelic model			Genotype model			
	A allele carriers	C allele non carriers	C allele carriers	AA	CA	CC	C allele non carriers	C allele carriers	T allele non carriers	T allele carriers	CC	TC	TT
Age at diagnosis, years													
<50	34	106	37	34	69	37	31	109	38	102	38	71	31
≥50	11	51	19	11	32	19	12	50	18	44	18	32	12
OR (95% CI)	1	0.67 (0.32-1.43)	1	1.23 (0.64-2.38)			1	0.84 (0.40-1.78)	1	1.09 (0.57-2.13)			
P-value		0.362		0.610	0.570			0.713		0.865			0.901
Tumour size, cm													
<2	32	98	36	32	62	36	31	99	36	94	36	63	31
2-5	13	59	20	13	39	20	12	60	20	52	20	40	12
OR (95% CI)	1	0.68 (0.33-1.39)	1	1.00 (0.53-1.91)			1	0.64 (0.31-1.34)	1	1.00 (0.53-1.91)			
P-value		0.297		>0.999	0.528			0.283		>0.999			0.475
Lymph node status													
Negative	28	94	34	28	60	34	27	95	34	88	34	61	27
Positive	17	63	22	17	41	22	16	64	22	58	22	42	16
OR (95% CI)	1	0.91 (0.46-1.79)	1	0.98 (0.52-1.84)			1	0.88 (0.44-1.76)	1	0.98 (0.52-1.84)			
P-value		0.863		>0.999	0.982			0.730		>0.999			0.911
Differentiation grade													
G1+G2	36	121	40	36	81	40	34	123	41	116	41	82	34
G3	9	35	15	9	20	15	9	35	14	30	14	21	9
OR (95% CI)	1	0.86 (0.38-1.97)	1	1.51 (0.74-3.11)			1	0.93 (0.41-2.12)	1	1.32 (0.64-2.73)			
P-value		0.839		0.339	0.563			>0.999		0.566			0.769
Estrogen receptor status													
Negative	14	50	17	14	33	17	14	50	15	49	15	35	14
Positive	31	107	39	31	68	39	29	109	41	97	41	68	29
OR (95% CI)	1	1.04 (0.51-2.11)	1	1.09 (0.56-2.12)			1	0.95 (0.46-1.95)	1	1.38 (0.69-2.74)			
P-value		>0.999		0.867	0.980			>0.999		0.401			0.675
Progesterone receptor status													
Negative	15	66	24	24	42	15	15	66	22	59	22	44	15
Positive	30	91	32	32	59	30	28	93	34	87	34	59	28
OR (95% CI)	1	1.45 (0.72-2.91)	1	0.85 (0.46-1.59)			1	1.33 (0.66-2.67)	1	1.05 (0.56-1.97)			
P-value		0.307		0.634	0.575			0.486		>0.999			0.662

Table SVI. Association between *VEGFA* rs1005230 and *VEGFA* rs25648 polymorphisms and clinicopathological features.

Parameter	VEGFA rs1005230						VEGFA rs25648						
	Allelic model			Genotype model			Allelic model			Genotype model			
	T allele carriers	C allele non carriers	C allele carriers	TT	CT	CC	C allele non carriers	C allele carriers	T allele non carriers	T allele carriers	CC	CT	TT
Age at diagnosis, years													
<50	35	38	102	38	67	35	2	138	96	44	96	42	2
≥50	11	18	44	18	33	11	2	60	36	26	36	24	2
OR (95% CI)	1	1	1.09 (0.57-2.13)	1	2.30 (0.32-16.7)	1	1	0.64 (0.34-1.18)	1	0.64 (0.34-1.18)	1	0.241	1
P-value	0.281	0.865		0.516			0.588			0.153			
Tumour size, cm													
<2	32	37	93	37	61	32	3	127	85	45	85	42	3
2-5	14	19	53	19	39	14	1	71	47	25	47	24	1
OR (95% CI)	1	1	1.00 (0.47-1.72)	1	0.59 (0.06-5.84)	1	1	0.99 (0.54-1.82)	1	0.99 (0.54-1.82)	1	>0.999	1
P-value	0.485	0.870		0.573			>0.999			>0.999			
Lymph node status													
Negative	28	34	88	34	60	28	3	119	85	37	85	34	3
Positive	18	22	58	22	40	18	1	79	47	33	47	32	1
OR (95% CI)	1	1	0.98 (0.52-1.84)	1	0.50 (0.05-4.91)	1	1	0.62 (0.34-1.12)	1	0.62 (0.34-1.12)	1	0.165	1
P-value	>0.999	>0.999		>0.999			>0.999			0.131			
Differentiation grade													
G1+G2	36	40	117	40	81	36	2	155	105	52	105	50	2
G3	10	15	29	15	19	10	1	43	27	17	27	16	1
OR (95% CI)	1	1	1.51 (0.74-3.11)	1	1.80 (0.16-20.3)	1	1	1.32 (0.79-1.57)	1	1.32 (0.79-1.57)	1	0.580	1
P-value	>0.999	0.339		0.510			0.525			0.590			
Estrogen receptor status													
Negative	15	16	48	16	33	15	0	64	42	22	42	22	0
Positive	31	40	98	40	67	31	4	134	90	48	90	44	4
OR (95% CI)	1	1	1.22 (0.62-2.40)	1	0.68 (0.62-0.75)	1	1	0.98 (0.53-1.83)	1	0.98 (0.53-1.83)	1	0.506	1
P-value	>0.999	0.615		0.834			0.310			>0.999			
Progesterone receptor status													
Negative	17	24	57	24	40	17	2	79	49	32	49	30	2
Positive	29	32	89	32	60	29	2	119	83	38	83	36	2
OR (95% CI)	1	1	0.85 (0.46-1.59)	1	0.66 (0.09-4.81)	1	1	1.43 (0.79-2.57)	1	1.43 (0.79-2.57)	1	0.479	1
P-value	0.733	0.634		0.833			>0.999			0.291			

